Can I Take Rhodiola With Losartan?

What losartan and rhodiola actually are

Losartan, sold under the brand name Cozaar, is an FDA-approved angiotensin II receptor blocker used to treat high blood pressure and, in specific populations, to protect the kidneys in type 2 diabetes and reduce stroke risk in patients with hypertension and left ventricular hypertrophy. It works by blocking the AT1 receptor for angiotensin II, which relaxes blood vessels and lowers blood pressure. Losartan is a prodrug: the liver enzyme CYP2C9 converts it into its more active metabolite, E-3174, which does most of the work.

Rhodiola rosea is a root used in traditional Scandinavian and Russian medicine, marketed in the United States as a dietary supplement rather than a drug. It is not reviewed or approved by the FDA for any medical indication, and manufacturing quality, standardization, and labeled potency vary between products. People commonly take it for fatigue, stress, and mild mood symptoms. Small human trials have reported cardiovascular and central nervous system effects, but the overall evidence base is limited in size and consistency, and a national reference body (NIH's National Center for Complementary and Integrative Health) describes rhodiola's evidence for most claimed uses as preliminary. (https://www.nccih.nih.gov/health/rhodiola)

Does rhodiola add to losartan's blood-pressure-lowering effect?

This is the central, practically relevant question, and the honest answer is: plausibly yes, but the size of the effect in a person also taking losartan has not been directly studied.

Losartan's blood-pressure-lowering effect is well established through the FDA approval process and decades of clinical use. Some small human trials of rhodiola extract have reported modest reductions in blood pressure or blood-pressure-related measures over several weeks, though trial sizes are small, extracts and doses vary between studies, and results are not fully consistent. No trial has tested rhodiola in people already taking losartan or another ARB, so there is no direct evidence on whether the two effects add together, and if so, by how much.

The pharmacologically reasonable expectation is additive, not synergistic, blood-pressure lowering: a supplement with its own mild hypotensive signal, layered on top of a prescription drug with a well-documented one, raises the practical risk of symptomatic low blood pressure (dizziness, lightheadedness on standing) more than either agent would alone, particularly in people who are already close to their blood pressure target, are over 65, or take more than one antihypertensive medication. This is the type of statement a pharmacist would flag as a moderate, monitorable interaction rather than a contraindication.

Could rhodiola change how losartan is metabolized?

This is the more speculative half of the interaction. Losartan depends on CYP2C9 for conversion to its active form. Some rhodiola constituents (rosavins) have shown weak effects on drug-metabolizing enzymes in laboratory (in vitro) studies, which is a common finding for many plant extracts and does not automatically translate into a meaningful effect in a person taking a normal oral dose. Whether rhodiola meaningfully inhibits or induces CYP2C9 in real-world use, and whether that would raise or lower a patient's exposure to active losartan, has not been established through human pharmacokinetic study in the material provided here. Until that data exists, this should be treated as a theoretical concern worth mentioning to a pharmacist, not a quantified risk.

People who are known CYP2C9 poor metabolizers, a genetically defined subgroup that already processes losartan more slowly, may be a group where any additional enzyme interference matters more, but the size of that effect for rhodiola specifically is not established.

Does rhodiola's effect on serotonin matter here?

Losartan has no serotonergic mechanism, so it does not itself interact with serotonin pathways. Rhodiola, however, has shown activity affecting monoamine systems (including serotonin and dopamine) in preclinical and laboratory research. That activity is not a concern for losartan directly, but it becomes relevant if you also take a serotonergic medication: an SSRI, SNRI, tricyclic antidepressant, or especially a monoamine oxidase inhibitor (MAOI) such as selegiline, phenelzine, or tranylcypromine. Combining rhodiola with an MAOI is the one scenario in this article with a clearer theoretical hazard (serotonin excess or hypertensive crisis) and should not be attempted without a specialist's explicit input.

Who should be more cautious, and who is lower risk

Higher caution is warranted if any of the following apply: blood pressure already at or near target on losartan, age over 65, use of two or more blood-pressure medications, use of an SSRI, SNRI, tricyclic antidepressant, or MAOI, a history of fainting or orthostatic hypotension, or pregnancy (losartan is contraindicated in pregnancy for fetal toxicity reasons, and rhodiola has no established pregnancy safety data).

A person with mild, well-controlled hypertension on a stable low dose of losartan, no other cardiovascular medications, and no antidepressant use represents a comparatively lower-risk profile, though "lower risk" is not the same as "no monitoring needed."

What is established, what is plausible, and what is not established

Rhodiola-losartan evidence-status assessment

Before starting or continuing this combination, verify with a prescriber or pharmacist:

• Your current blood pressure control and whether you are already near target
• Whether you take any other blood-pressure-lowering drug, SSRI, SNRI, or MAOI
• The specific rhodiola product and its labeled standardization, since potency varies widely between brands
• Your kidney function and electrolyte monitoring schedule, which should already be in place for anyone on losartan
• Whether a baseline and short-term follow-up blood pressure check can be arranged

A practical, cautious approach if your clinician agrees to the combination

No published guideline specifies exact parameters for using rhodiola alongside losartan. The following is a conservative, common-sense monitoring approach, not a validated protocol, and it does not substitute for your own clinician's judgment:

1. Get a baseline seated and standing blood pressure reading before starting rhodiola.
2. If your clinician agrees to proceed, consider starting at the lower end of a product's labeled dose rather than the highest labeled amount.
3. Recheck seated and standing blood pressure roughly one to two weeks after starting. A standing systolic drop of 20 mmHg or more, or a diastolic drop of 10 mmHg or more, meets the general clinical definition of orthostatic hypotension and warrants a call to your clinician.
4. Report new dizziness, fainting, unusual agitation, tremor, rapid heartbeat, or excessive sweating promptly, especially if you also take an antidepressant.
5. Keep your full supplement list current at every prescriber visit. Supplements are often started or stopped between appointments without the prescriber's knowledge.

When to seek urgent care

Contact emergency medical services immediately if you experience fainting, chest pain, severe or persistent dizziness, a very rapid or irregular heartbeat, or signs of serotonin syndrome (agitation, high fever, muscle rigidity, rapid heart rate) after beginning or modifying your losartan or rhodiola regimen. Do not try to handle these symptoms on your own by modifying your supplement or medication dosage.

Evidence boundary

Established: losartan's mechanism and approved use as an antihypertensive; rhodiola's general standing as an under-regulated dietary supplement with a limited but real human evidence base for fatigue and, in some small trials, blood pressure.

Plausible but unproven: additive blood-pressure lowering when the two are combined; a minor pharmacokinetic effect on losartan's activation via CYP2C9.

Not established: any specific numeric interaction rate, a validated safe rhodiola dose for people on losartan, or human data confirming a serotonergic risk from rhodiola and losartan absent a third serotonergic drug.

Frequently asked questions

References

2. National Center for Complementary and Integrative Health, National Institutes of Health. Rhodiola. Available from: https://www.nccih.nih.gov/health/rhodiola
3. Endocrine Society. Clinical practice guidelines (general reference on evaluating supplement use alongside prescribed therapy). Available from: https://www.endocrine.org/clinical-practice-guidelines

Several claims about specific trial results, enzyme kinetics, and quoted expert statements that appeared in an earlier version of this article could not be verified against a located primary source and have been removed or rewritten as general, unquantified statements pending editorial and qualified medical review. This article does not describe a scenario where a specific individual's dosing or diagnosis can be determined without direct clinical evaluation.